Phosphonate compounds
View Patent ↗The present invention relates to phosphonate compounds, compositions containing them, processes for obtaining them, and their use for treating a variety of medical disorders, e.g., osteoporosis and other disorders of bone metabolism, cancer, viral infections, and the like.
1. A compound selected from the group consisting of a phosphonate of an antiviral compound of the formula:
wherein
R 1 is hydrogen, —CH 3 , —CH 2 OH, —CH 2 F, —CH═CH 2 , or —CH 2 N 3 ;
R 8 is hydrogen; and
B is guanin-9-yl, adenin-9-yl, 2,6-diaminopurin-9-yl, 2-aminopurin-9-yl or their 1-deaza, 3-deaza, or 8-aza compounds, or B is cytosin-1-yl;
covalently linked to an alkylglycerol, alkyipropanediol, 1-S-alkylthioglycerol, alkoxyalkanol or alkylethanediol.
2. The compound of claim 1 , wherein R 1 is hydrogen and B is guanin-9-yl.
3. The compound of claim 1 that is covalently linked to alkylglycerol.
4. The compound of claim 1 that is covalently linked to alkylpropanediol.
5. The compound of claim 1 that is covalently linked to 1-S-alkyithioglycerol.
6. The compound of claim 1 that is covalently linked to alkoxyalkanol.
7. The compound of claim 1 that is covalently linked to alkylethanediol.
8. The compound of claim 1 that is covalently linked to hexadecyipropanediol.
9. The compound of claim 1 that is covalently linked to octadecylpropanediol.
10. The compound of claim 1 , wherein R 1 is —CH 2 OH and B is adenin-9-yl.
11. The compound of claim 1 that is covalently linked to alkylglycerol.
12. The compound of claim 1 that is covalently linked to alkylpropanediol.
13. The compound of claim 1 that is covalently linked to 1-S-alkylthioglycerol.
14. The compound of claim 1 that is covalently linked to alkoxyalkanol.
15. The compound of claim 1 that is covalently linked to alkylethanediol.
16. The compound of claim 1 that is covalently linked to hexadecylpropanediol.
17. The compound of claim 1 that is covalently linked to octadecylpropanediol.
18. A pharmaceutical composition comprising an effective amount of an antiviral phosphonate compound of claim 1 in combination with a pharmaceutically acceptable carrier.
19. The pharmaceutical composition of claim 18 in a solid dosage form.
20. The pharmaceutical composition of claim 18 in a capsule, tablet, aerosol, solution, suspension or in a topical formulation.